Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KU 60019

Known as: KU-60019, KU60019 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
BackgroundMYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2019
2019
Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells
Despite advances in glioblastoma (GBM) therapy, prognosis of the disease remains poor with a low survival rate. Cannabidiol (CBD… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019
We have recently reported that glioblastoma (GB)‐initiating cells (GIC) with low expression and/or mutation of TP53 and high… Expand
2015
2015
Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
Ataxia telangiectasia mutated (ATM) is an important signaling molecule in the DNA damage response (DDR). ATM loss of function can… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
Predictability, efficacy and safety of radiosensitization of glioblastoma‐initiating cells by the ATM inhibitor KU‐60019
We have previously shown that pharmacological inhibition of ataxia telangiectasia mutated (ATM) protein sensitizes glioblastoma… Expand
2014
2014
Improved ataxia telangiectasia mutated kinase inhibitor KU60019 provides a promising treatment strategy for non-invasive breast cancer
It has previously been reported that KU60019, as a highly effective radiosensitizer, inhibits the DNA damage response and blocks… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Purpose: Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of only 12 to 15 months… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control
Glioblastoma multiforme (GBM) is notoriously resistant to treatment. Therefore, new treatment strategies are urgently needed. ATM… Expand
2011
2011
CGK733 does not inhibit ATM or ATR kinase activity in H460 human lung cancer cells.
Dear Editor, The purpose of this letter is to address the activity of CGK733, a small molecule that was reported to inhibit… Expand
Highly Cited
2009
Highly Cited
2009
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
Ataxia telangiectasia (A-T) mutated (ATM) is critical for cell cycle checkpoints and DNA repair. Thus, specific small molecule… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE